
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded liquid for feeding-tube use containing lansoprazole, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing lansoprazole are listed in capsule and tablet forms. It is also a component of FDA-approved kits.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Lansoprazole is a proton pump inhibitor that lowers stomach acid; compounding pharmacies most often prepare it as an oral suspension.
Lansoprazole is a proton pump inhibitor (PPI). It is a prodrug that is activated in the acid-producing parietal cells of the stomach, where it blocks the proton pump, the final step of acid secretion. Prevacid delayed-release capsules and Prevacid SoluTab orally disintegrating tablets (Takeda) are FDA-approved for duodenal and gastric ulcers, healing and risk reduction of NSAID-associated gastric ulcers, H. pylori eradication as part of combination therapy, symptomatic GERD, erosive esophagitis and its maintenance, and Zollinger-Ellison syndrome. A nonprescription version is sold for frequent heartburn. There is no manufactured liquid form, so a prescriber may order lansoprazole compounded as an oral suspension for a child or for someone who needs a liquid. Compounded preparations are not FDA-approved and require a prescription.
Lansoprazole does not carry a boxed warning. Do not take it if you are allergic to any of its ingredients or take rilpivirine, an HIV medicine. The label warns about kidney inflammation, severe diarrhea from C. difficile, serious skin reactions, lupus, and, with long-term use, bone fractures of the hip, wrist or spine, low magnesium and low vitamin B12. Lansoprazole can change how other drugs work, including warfarin, high-dose methotrexate, tacrolimus, theophylline, and medicines that need stomach acid to be absorbed. Available pregnancy data do not show a link to adverse outcomes. LactMed reports no information on use during breastfeeding but notes lansoprazole has been used in newborns, so the amount in milk is unlikely to be harmful. Talk to your prescriber or pharmacist if you get severe watery diarrhea, a rash, irregular heartbeat or seizures.
Lansoprazole is a substituted benzimidazole that blocks the parietal cell H+/K+ ATPase after acid-catalyzed activation in the secretory canaliculi. Per the Prevacid label, absolute bioavailability is over 80%, Cmax and AUC fall by about 50 to 70% when given 30 minutes after food (no significant effect when given before meals), protein binding is 97%, and plasma half-life is under two hours. It is metabolized by CYP2C19 and CYP3A4, so inducers and inhibitors of these enzymes may alter exposure. Labeled indications are those of Prevacid capsules and SoluTab listed above. Prescribers have ordered compounded lansoprazole oral suspension in a sodium bicarbonate vehicle, mainly for children; one analytical study described it as the most frequently reported extemporaneous formulation prepared in the inpatient setting. Lansoprazole is unstable in acidic media. Dosing is per prescriber. Label warnings to watch for include hypomagnesemia, B12 deficiency with long-term use, C. difficile diarrhea, acute tubulointerstitial nephritis, and interference with investigations for neuroendocrine tumors. Lansoprazole is not a controlled substance.
Shake the bottle if your label says to. Draw the dose into the syringe provided. Flush the tube with water before giving the dose, give the medication, then flush again with water as your care team directs. Give each medication separately unless told otherwise. Never give slow release or extended release products through a tube.
G tube liquids are usually aqueous. Under USP <795>, a preserved aqueous preparation carries a beyond-use date of up to 35 days and an unpreserved one 14 days refrigerated. Your label shows whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.